Injection of mice with the attenuated bovine vaccine Brucella abortus 19 results in a chronic infection, which was one of the early models of cell-mediated immunity (9) . The bacteria survive within macrophages of the spleen and, to a lesser extent, the liver and bone marrow. The level of infection is controlled by activation of those cells by lymphokines produced by T lymphocytes. After the initial decline in bacterial numbers coinciding with the onset of cell-mediated immunity, there persists for some time a steady infection of about 106 bacteria per spleen (3) . Both before and after the onset of cell-mediated immunity, macrophages and neutrophils are essential effector cells.
The maturation of these phagocytic cells is dependent on colony-stimulating factors (CSF), a group of cell growth factors that regulate the proliferation and differentiation of hemopoietic precursor cells into macrophages, neutrophils, and other end cells (10) . These precursor cells are known as colony-forming cells (CFC) because of their ability to form colonies in semisolid agar under the influence of CSF. In mice infected with B. abortus 19, CSF in the serum and CFC in the spleen and bone marrow reach a peak 2 to 3 weeks after infection (4) . However, CSF and CFC return to normal levels 4 weeks after infection despite the presence of up to 106 bacteria per spleen. It is not clear what the mechanism of this is or whether it is the reason for the chronicity of the infection.
Recent reports have shown that interleukin-1 (IL-1) given before injection of mice with any one of a number of pathogenic bacteria enhances resistance to subsequent infection (5, 13) . This is related, at least in part, to increased colony-stimulating activity (CSA) in serum and increased numbers of CFC in treated mice (7, 12, 19) . We therefore set out to test whether IL-1 given before infection or during chronic infection would enhance the resistance of mice to B. abortus. In particular, the effect of IL-1 during chronic infection would tell us whether the mice had become refrac-* Corresponding author.
tory to further production of CSFs, as has been suggested (14) , or, if not, whether enhancing production of macrophages would lead to early recovery from infection. These questions are relevant to the possibilities for therapy of similar infections, such as tuberculosis and leprosy.
MATERIALS AND METHODS
Mice and bacterial infection. CBA/H mice were bred in the Microbiology Animal Breeding Unit, University of Melbourne, Australia, by strict brother-sister mating. The mice were sex matched within experiments and were infected at 6 weeks of age. The vaccine strain of B. abortus 19 (Commonwealth Serum Laboratories, Parkville, Australia) was maintained by weekly subculture on horse blood agar (HBA) and renewed from freeze-dried stock after 25 passages. Twentyfour-hour cultures were washed from the plates with sterile saline. The inoculum was standardized turbidometrically to 5 x 105 CFU per mouse for chronic infection or 2 x 104 CFU per mouse for acute infection and injected intravenously in 0.2 ml. The dose was checked retrospectively by viable counts on HBA plates. At various times after infection, the mice were killed by fluothane anaesthesia, and spleens and livers were removed aseptically and homogenized in 5 ml of sterile distilled water in sealed containers with an UltraTurrax homogenizer (Janke and Kunkel, Breisgau, Germany). After appropriate dilution, samples were plated onto HBA, and colonies were counted after 72 h to give a count of viable bacteria.
IL-1. Human recombinant IL-1 a was the generous gift of P. J. Lomedico (Hoffman-La Roche, Nutley, N.J.). The lyophilized material was reconstituted to 2 x 108 U/ml (D1O assay; protein concentration, 0.68 mg/ml; endotoxin, <0.5 EU/ml) with pyrogen-free saline (Astra, North Ryde, New South Wales, Australia) and stored at 4°C. Previous experiments showed 105 U per mouse as the optimal dose. The control groups of mice received pyrogen-free saline.
Bioassay for CSA. Mice were bled from the heart under fluothane anesthesia. For CSA, serum was pooled within CSF-1 radioimmunoassay. Highly purified CSF-1 was radioiodinated as described previously for use in a radioimmunoassay (18) . For the CSF-1 assay, sera were collected from individual mice. The concentration of CSF-1 in serum samples from individual mice was assayed by a specific radioimmunoassay as described in detail elsewhere (17) .
CFC assay. Bone marrow cells were prepared as described above. Spleen cells were prepared by teasing the spleen into IMDM-FCS and passing the cells through an 80-mesh stainless steel sieve. The cells were centrifuged at 800 x g for 7 min, suspended in Tris-buffered 0.83% ammonium chloride to lyse erythrocytes, underlaid with 1 ml of FCS to remove debris, and centrifuged again. Viable cells were counted by eosin exclusion and diluted appropriately in IMDM-FCS. The agar culture system used to assay CFC was similar to that described by Metcalf et al. (11) . Spleen and bone marrow cells were assayed for CFC by using triplicate 1-ml cultures containing 5 x 10' viable bone marrow cells or 106 viable spleen cells in 35-mm-diameter petri dishes (Falcon Products, Becton-Dickson Labware, Oxnard, Calif.) in 1 ml of semisolid agar with IMDM-FCS. A source of CSF was supplied by 0.1 ml of a 1/4 dilution of pooled serum from C57BL/10 mice injected 6 h previously with 5 ,ug of lipopolysaccharide w (Escherichia coli O11:B4; Difco Laboratories, Detroit, Mich.). After 6 days of incubation, colonies were counted under a dissecting microscope (magnification, x200). Only colonies containing more than 50 cells were scored.
Staining of spleen cells. Cytocentrifuge smears were prepared by placing 200 RI of FCS and 4 x 104 spleen cells into a cytocentrifuge chamber and spinning at 44 x g for 10 min. For differential cell counts, cytocentrifuge smears were fixed in methanol for 5 min and stained with Diff-Quik (AHS, Australia), dried, and mounted in DPX (BDH Chemical, Australia). Slides were examined under oil immersion at x 800 magnification. Differential cell counts were determined by counting at least 200 cells. For myeloperoxidase staining, the smears were fixed with formol-ethanol for 1 min and stained with a benzidine dihydrochloride mixture as described by Kaplow (8) . The slides were dried, mounted in DPX, and examined under oil immersion at x800 magnification. At least 500 cells were counted; any cells containing blue granules were considered positive for myeloperoxidase. (Fig. 1) . Four repeated experiments showed similar results. The IL-1 had no effect on the initial localization measured at 2 h. However, by day 4 after infection, IL-1 treatment had significantly depressed the growth in bacterial numbers, and protection was maintained for the 14 days of observation, when there was a 40-fold difference in bacterial numbers between treated and untreated groups. The effect on bacterial number was more marked in spleens than in livers, in which the infection is more readily resolved even in untreated mice.
Mice that had been infected with B. abortus 4 weeks earlier still carried many organisms. When mice were treated with IL-1 as described above or with an even higher dose (106 U), bacterial numbers in spleen and liver did not change significantly, averaging around 3 x 105/spleen and 1 x 103/liver regardless of treatment (data not shown). The time of IL-1 administration was in fact found to be critical to the efficacy of IL-1. When mice were injected only 1 day after infection, no depression in bacterial numbers was observed over a 14-day period after infection. Significant protection was observed only when IL-1 was administered before infection.
Effect of IL-1 on CSA in serum. We have previously shown that brucella infection results in increased CSA in serum 1 to 3 weeks later but that the level declines by 4 weeks postinfection (4) . The effect of IL-1 on CSA in serum was therefore tested in three categories of mice: normal, acutely infected, and chronically (4 weeks) infected. Total serum CSA was measured by the bone marrow proliferation assay, whereas the radioimmunoassay was used to measure specifically CSF-1. Experiments were performed three times with similar results.
When IL-1 was injected into normal mice, the CSA in serum increased dramatically 2 h later (Fig. 2) . This increase in the CSA in serum gradually subsided but was still measurable at 6 and 12 h. Mice infected 4 h after IL-1 injection showed increased CSA 6 h after IL-1 injection compared with that in infected but untreated mice (Fig. 3) . By 12 h after IL-1 injection, the effect of infection alone overtook that of IL-1 pretreatment. Figure 4 shows the contrasting situation in normal and chronically infected mice injected with IL-1. Whereas at 2 h after injection of normal mice, there was the usual marked increase in CSA, the increase in 28-day-infected mice was modest (5-fold difference in peak counts per minute compared with 45-fold in the normal mice). At 6 h, the CSA levels in IL-1-treated mice were similar in normal and chronically infected mice.
These results were broadly confirmed by specific measurement of CSF-1 with the radioimmunoassay. Levels of CSF-1 in chronically infected mice were actually below the level in normal mice throughout, but the level was markedly increased by IL-1 treatment (Table 1) . Serum from acutely infected mice also showed an early depression in CSF-1, which was mitigated by IL-1 treatment. Thus, 2 h after infection, untreated mice had only 450 + 212 U of CSF-1 per ml, compared with 2,160 ± 1,486 U/ml in normal mice. Mice given IL-1 4 h before infection developed 1,210 ± 460 U/ml. By 8 h after infection (12 h after IL-1 injection), untreated mice had 3,613 ± 3,327 U of CSF-1 per ml and treated mice had 2,733 + 1,963 U/ml.
Effect of IL-1 on CFC in spleen and bone marrow. Intravenous injection of IL-1 into normal mice, mice infected 4 h later, or mice carrying a 28-day infection increased the numbers of CFC in the spleen in all three groups as early as 1 day after treatment (Fig. 5) . The effect was even greater at 4 days. Although a marked increase in the number of spleen CFC was seen in each of four experiments, the effect on IL-1 bone marrow CFC was variable, occurring in only two of the four experiments, and led to not more than a twofold increase (data not shown).
Effect of IL-1 on cell composition in spleen. To quantify the newly formed monocytes and polymorphonuclear cells in the spleen, cells were stained for myeloperoxidase, a bactericidal enzyme found in polymorphs and newly formed (19) . We compared both total CSA (measured by bone marrow assay) and CSF-1 (measured by radioimmunoassay) in normal mice, acutely infected mice, and chronically infected mice. By both assays, there was a sharp increase in CSF 2 h after giving IL-1, with levels declining but remaining above normal for at least 12 h. The relatively large standard deviations in the radioimmunoassay results reflected mouse-to-mouse variation.
The fact that the increase in CSF-1 was detected by the radioimmunoassay is important, since the radioimmunoassay, unlike bioassays, is not influenced by synergistic or inhibitory effects. IL-1 can act synergistically with some CSFs in vitro (21) , and the apparent rise in total CSA could have been attributed to residual IL-1. Similarly, the increase in CSF-1 could not be due to removal of an inhibitor, which has been reported with a CFC assay (1) .
When mice were challenged with Brucella organisms 4 h after IL-1 injection, the IL-1-treated mice retained an advantage over untreated mice in terms of total CSA until the infection itself began to stimulate CSA in the serum. Curiously, infection had an initial depressing effect on specific CSF-1, although levels of CSF-1 were higher in the IL-1-pretreated mice. Whether this apparent removal of CSF-1 from circulation could be due to rapid upregulation of macrophage CSF-1 receptors as a result of infection or whether it is due to some other mechanism could only be settled by further experiments. By 24 h, CSF-1 in infected mice is well above normal (3a) .
When IL-1 was injected into mice already carrying a chronic (28-day) infection, the dramatic increase in total CSA did not occur at 2 h. The effect on total CSA is unlikely to be due to its removal from circulation, since at 6 and 12 h the levels in normal and chronically infected mice were similar. It 
